Regenerative nanomedicines: an emerging investment prospective?
Cells respond to their structural surrounding and within nanostructures exhibit unique proliferative and differentiation properties. The application of nanotechnologies to the field of regenerative medicine offers the potential to direct cell fate, target the delivery of cells and reduce immune rejection (via encapsulation), thereby supporting the development of regenerative medicines. The overall objective of any therapy is the delivery of the product not just into the clinic but also to patients on a routine basis. Such a goal typically requires a commercial vehicle and substantial levels of investment in scientific, clinical, regulatory and business expertise, resources, time and funding. Therefore, this paper focuses on some of the challenges facing this emerging industry, including investment by the venture capital community.
Prescott
Catherine
C
Biolatris Ltd, St John's Innovation Centre, Cowley Road, Cambridge CB4 0WS, UK. cprescott@biolatris.com
D018929:Cell Culture Techniques; D005378:Financial Support; D005544:Forecasting; D050997:Nanomedicine / Q000191:economics* / Q000639:trends; D044968:Regenerative Medicine / Q000191:economics* / Q000639:trends; D057905:Stem Cell Research / Q000191:economics; D013234:Stem Cells / Q000166:cytology
Nat Biotechnol. 2009 Nov;27(11):977-9
19898444
Nat Biotechnol. 2005 Jul;23(7):817-9
16003363
Proc Natl Acad Sci U S A. 2009 Feb 17;106(7):2130-5
19179282
Int J Nanomedicine. 2007;2(4):623-38
18203429
J Neurosurg. 2008 Feb;108(2):320-9
18240929
Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2009 Mar-Apr;1(2):226-36
20049793
J Biomed Mater Res A. 2009 Sep 15;90(4):1252-61
19585563